R. Feenstra

Allosteric Inhibition of the Neuropeptidase Neurolysin*

Paul N. Mortenson, J. Lange, C. Kruse, 2014, The Journal of Biological Chemistry.

SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug

J. Glennon, H. Meltzer, C. Kruse, 2007, Neuropsychopharmacology.

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.

K. Marquis, S. Grauer, J. Brennan, 2009, Bioorganic & medicinal chemistry letters.

In vitro characterization of SLV308 (7‐[4‐methyl‐1‐piperazinyl]‐2(3H)‐benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5‐HT1A receptor agonist

E. Ronken, J. Reinders, M. Hesselink, 2006, Synapse.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

K. Marquis, S. Grauer, J. Brennan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Newborn Rat Nucleus Basalis Neurons Channels in Cultured 2+ High-Voltage-Activated Ca Neurotensin and Substance P Inhibit Low- and

Paul N. Mortenson, J. Lange, K. Koyano, 2015 .

New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.

C. Kruse, W. Kuipers, M. Tulp, 2001, Bioorganic & medicinal chemistry letters.